GlassScriptPhysician profile
Magan King
NPI 1841574001
$8,519.71
in general payments reported to CMS, 2019-2025
27 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,494 · 2022: $814 · 2023: $3,020 · 2024: $1,717 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824 · Travel and Lodging: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,823.92 |
| Travel and Lodging | $1,388.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,064.70 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Relievant Medsystems, INC. | $1,674.57 | 2023 | Intracept |
| Boston Scientific Corporation | $1,198.25 | 2021-2025 | Intracept, General - Pain Management |
| Abbvie INC. | $622.26 | 2021-2025 | |
| Abbott Laboratories | $295.67 | 2023-2025 | Proclaim |
| Pfizer INC. | $226.70 | 2023-2025 | |
| Si-Bone, INC. | $224.69 | 2021-2024 | |
| Saluda Medical Americas, INC. | $170.44 | 2025 | Evoke |
| Collegium Pharmaceutical, INC. | $161.60 | 2021-2025 | Xtampza |
| Nalu Medical, INC. | $134.78 | 2022-2023 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $134.55 | 2023 | Sprint Pns System |
| Spinal Simplicity, LLC | $127.93 | 2023 | Ha Minuteman G3-R |
| Biohaven Pharmaceutical Holding Company LTD. | $124.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $47.20 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $42.84 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $39.01 | 2021 | |
| Lilly USA, LLC | $35.75 | 2021-2023 | Emgality, Reyvow |
| Arbor Pharmaceuticals, INC. | $35.21 | 2021 | |
| Averitas Pharma INC. | $35.20 | 2023 | Qutenza |
| Acacia Pharma INC | $24.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.79 | 2021 | |
| Horizon Therapeutics Plc | $14.97 | 2021 | |
| International Rehabilitative Sciences, INC | $14.73 | 2024 | Rs 4i Plus Sequential Stimulator |
| Kowa Pharmaceuticals America, INC. | $14.06 | 2023 | Seglentis |
| Baudax Bio INC. | $13.88 | 2021 | |
| Biodelivery Sciences International, INC. | $12.98 | 2021 | |
| Lundbeck LLC | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.